There are no generic forms of Zecuity (sumatriptan transdermal) available at this time. A generic version of this drug is not expected to become available until after the patents expire, which is not until February 2023. Although sumatriptan is sometimes called the "generic name" for Zecuity, it is simply the active ingredient and not a generic version of it.
Zecuity™ (sumatriptan transdermal) is a prescription medication approved to treat migraine headaches. It belongs to a group of medicines known as triptans.
Zecuity is manufactured by NuPathe, Inc. It is currently protected by patents that prevent any generic versions from being manufactured in the United States.
The first patent for Zecuity is set to expire in February 2023. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to delay or shorten this exclusivity period. This could include things such as lawsuits or other patents for new Zecuity uses. Once the patent expires, there may be several companies that manufacture a generic Zecuity drug.
No -- sumatriptan is the active ingredient in Zecuity, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.
Sumatriptan is also an active ingredient in several other products, including the brand-name medicines Alsuma®, Imitrex®, Sumavel®, and Treximet®. Although these products are not interchangeable with Zecuity, they may be a more affordable option for some people. Some of these other sumatriptan products are available in generic form.
See the following articles to learn more about the generic availability of other sumatriptan medicines: